Post by Lonza

Microbial manufacturing is entering a new era defined by increasing scale, process complexity, and rising demand for flexible production platforms. In a recent Q&A published in Discover Pharma, Axel Erler, Head of Commercial Development and Technical Sales, Microbial Biopharmaceuticals, explored how the microbial landscape is evolving and what it takes for CDMOs like Lonza to meet the needs of an advanced biologics market. He discussed: • Growing demand for scalable and adaptable microbial production systems to support a broader range of biologics and therapeutic modalities • Increasing process complexity driven by higher quality expectations, intensified upstream/downstream processes, and more diverse molecule types • How advances in process optimization, digital tools, and integrated manufacturing strategies are helping CDMOs improve efficiency, consistency, and time-to-market Read the full article: https://ow.ly/VAWE50ZgRLn #Lonza #CDMO #Microbial